摘要
目的探讨孟鲁司特钠联合布地奈德对支气管哮喘的临床疗效,并分析其对患者肺功能与生活质量的影响。方法选取2014年9月—2015年12月期间所收治的81例支气管哮喘患者作为该次研究病例,按照随机数字表法将其分为研究组和对照组,研究组41例,对照组40例,对照组患者应用布地奈德治疗,研究组患者在此基础上加用孟鲁司特钠治疗,对比分析两组患者的肺功能指标,并对两组患者治疗后哮喘症状评分、咳嗽评分、睡眠评分及症状、体征消失时间进行比较。结果治疗前两组肺功能指标差异无统计学意义(P>0.05),治疗后两组的肺功能指标均优于治疗前,差异有统计学意义(P<0.05),且研究组FEV1/FVC(72.83±3.04)%以及PEF(74.93±5.17)%均高于对照组(67.58±2.03)%;(68.58±5.03)%,经t检验差异有统计学意义(t=9.117 1,5.601 0,P<0.05);研究组治疗后哮喘症状评分、咳嗽评分、睡眠评分及症状、体征消失时间均低于对照组,组间差异有统计学意义。结论支气管哮喘患者采用孟鲁司特钠联合布地奈德治疗对比单用布地奈德治疗能够获得更优的效果,可以对患者的肺功能进行有效改善,并提升患者的生活质量,呈现应用价值。
Objective This paper tries to investigate the clinical efficacy of montelukast sodium and budesonide on bronchial asthma and to analyze its effect on lung function and quality of life in patients. Methods Eighty-one patients with bronchial asthma treated from September 2014 to December 2015 were selected as the study case. According to the random number table method, they were divided into study group and control group. There were 41 cases in the study group and 40 cases in the control group. The patients in the control group were treated with budesonide, and the patients in the study group were treated with montelukast sodium. The lung func-tion indexes of the two groups were analyzed and compared, and the symptoms of asthma symptoms after treatment, cough score, and sleep scores and comparison of symptoms and signs disappeared were compared. Results Before the treatment, there was no significant difference in the lung function indexes between the two groups（P〉0.05）. After the treatment, the lung function indexes of the two groups were better than those before the treatment. The differences were statistically significant（P〈0.05）. The study group had high FEV1/FVC（72.83±3.04）% and PEF（74.93±5.17）%. In the control group（67.58±2.03）%; 68.58±5.03）%, the t-test,the difference was statistically（t=9.117 1, 5.601 0,P〈0.05）; asthmatic symptom score, cough score, sleep score, and the disappearance time of symptoms and signs in the study group were all Lower than the control group, statistical significance exists between the groups. Conclusion The use of montelukast sodium combined with budesonide in the treatment of bronchial asthma patients with budesonide alone can achieve better results, can effectively improve the patient＇s lung function, and improve the quality of life of patients, showing application value.
作者
王丽艳
WANG Li-yan(Department of Respiratory Medicine,Ganmei Hospital,First People＇s Hospital of Kunming,Yunnan Province,650000 Chin)
出处
《世界复合医学》
2018年第2期18-20,共3页
World Journal of Complex Medicine
关键词
孟鲁司特钠
布地奈德
支气管哮喘
肺功能
生活质量
Montolukast sodium
Budosonido
Bronchial asthma
Pulmonary function
Quality of lifo
